While Wall Street obsesses over GLP-1 weight-loss drugs, Novo Nordisk's foundational diabetes business continues to deliver robust growth and exceptional returns on assets, presenting a durable investment thesis often overshadowed by the obesity narrative.
Facing the looming patent expiration of key drugs Revlimid and Eliquis, Bristol-Myers Squibb is making a strategic pivot, acquiring Orbital Therapeutics for $1.5 billion to pioneer in vivo RNA therapies. This high-stakes move aims to redefine the company's growth in oncology and autoimmune diseases.
AbbVie's $2.1 billion acquisition of Capstan Therapeutics signals a strategic pivot towards next-generation immunology treatments. The move aims to secure future revenue streams as the company navigates the post-Humira era, with analysts highlighting the transformative potential of its in vivo CAR-T platform.
As AI infrastructure spending accelerates, Arista Networks (ANET) is drawing investor attention with its debt-free balance sheet and critical role in cloud networking. Despite premium valuations, bulls argue its financial fortress and recurring software revenue justify the price, with a $163 price target signaling further upside.
Exclusive BBC analysis reveals nearly half of accredited zoos and aquariums in the UK and Ireland have sounded financial alarms since 2022, forcing tough choices between conservation missions and economic reality.
A recent SEC filing reveals a major purchase of the Vanguard 0-3 Month Treasury Bill ETF, signaling a strategic move for liquidity and yield in a volatile market.
Elon Musk consolidates his space and artificial intelligence ventures, with SpaceX acquiring xAI to form a private sector titan valued over a trillion dollars, aiming to solve AI's energy crisis by moving compute to space.
Bill and Hillary Clinton have agreed to appear before the House Oversight Committee as part of its investigation into the Jeffrey Epstein case, a spokesperson confirmed, signaling a major development in the long-running inquiry.
In an exclusive interview, GeneDx CEO Katherine Stueland details how rapid genomic testing is transforming pediatric care, slashing diagnosis times from years to days and building a data-driven bridge to future therapies.
Woodward (WWD) kicked off fiscal 2026 with robust earnings, driven by a surge in aerospace services and industrial sales. The company raised its full-year outlook but cautioned on supply chain pressures and announced a strategic wind-down of its volatile China On-Highway business.
Palantir Technologies' stock gained momentum Monday following an upgrade by William Blair, a move vindicated after hours by a strong Q4 earnings report that exceeded forecasts and set robust guidance for 2026.
A recent adjustment to Ceres Power Holdings' price target by analysts signals a broader reassessment of the clean energy firm's market narrative and future trajectory, moving beyond a single figure to underlying story shifts.
Merck & Co. is laying the groundwork for its future in oncology beyond Keytruda, announcing a strategic investment in biotech Eikon Therapeutics and a major collaboration with diagnostic leader Guardant Health. The moves signal a targeted, partnership-driven strategy to bolster its pipeline and diagnostics capabilities in the competitive cancer therapy market.
Investment firm Hussman Strategic Advisors has liquidated its entire stake in TG Therapeutics, a move that comes as the biotech's stock lags behind broader market gains despite reporting strong revenue growth for its flagship product.
Amidst a complex macroeconomic backdrop, a select group of Asian small-cap stocks is capturing attention for their distinct value propositions and growth narratives. We examine China Feihe, Digital China Holdings, and Thai Beverage, assessing their financial health and strategic positioning in volatile markets.
A high-stakes White House meeting between crypto executives and traditional bankers ended without a breakthrough on the contentious issue of stablecoin yields, casting doubt on the timeline for comprehensive market structure legislation. Both sides agreed to continue negotiations under pressure from the administration to reach a compromise this month.
Natural gas futures tumbled over 25% on Monday, hitting a three-week low, as a swift recovery in U.S. production and a warmer weather forecast alleviated supply concerns sparked by last week's Arctic blast.
HubSpot CEO Yamini Rangan acknowledges the breakneck pace of change in tech roles but argues the core value of education—learning how to think and solve problems—remains timeless, even as she guides her own son into the field.
As Palantir Technologies reports a massive surge in U.S. government revenue, CEO Alex Karp publicly defends the company's controversial surveillance platforms, insisting they contain safeguards against overreach. The defense comes amidst growing public and political scrutiny over its contracts with immigration enforcement agencies.
A man wanted for a fatal shooting in Camarillo led authorities on a dangerous pursuit reaching speeds over 100 mph before being found deceased in his vehicle, officials confirm.
